Anthony Letai, M.D., Ph.D. & Joan Montero, Ph.D.

Funded in Collaboration with Stand Up To Cancer (SU2C)

Every cancer is unique pointing to the need for personalized medicine. In oncology, a fundamental challenge is to assign the right treatment to every patient due to cancers’ biological complexity and the lack of effective predictive biomarkers. At the Letai lab we developed a functional predictive assay called Dynamic BH3 Profiling to rapidly test different treatments prior to giving them to the patient. It has already been successfully proved as an excellent predictor in different types of cancer, including melanoma. We aim to combine sophisticated genomic analyses with this novel test to improve melanoma treatment, improving patients’ clinical outcome, clinical trials and drug development.

Location: Dana-Farber Cancer Institute - Massachusetts
Proposal: Personalizing melanoma treatment using Dynamic BH3 Profiling
Mailing List Mailing List
Close Mailing List